Nothing Special   »   [go: up one dir, main page]

ECSP20070185A - Análogos novedosos de glp-1 - Google Patents

Análogos novedosos de glp-1

Info

Publication number
ECSP20070185A
ECSP20070185A ECSENADI202070185A ECDI202070185A ECSP20070185A EC SP20070185 A ECSP20070185 A EC SP20070185A EC SENADI202070185 A ECSENADI202070185 A EC SENADI202070185A EC DI202070185 A ECDI202070185 A EC DI202070185A EC SP20070185 A ECSP20070185 A EC SP20070185A
Authority
EC
Ecuador
Prior art keywords
analogs
glp
action
new
present disclosure
Prior art date
Application number
ECSENADI202070185A
Other languages
English (en)
Inventor
Ravishankara Madavati Nagaraja
Kunal Pandya
Abhishek Tiwari
Rishit Mansukhlal Zalawadia
Nishith Chaturvedi
Vinod Sampatrao Burade
Dhiren Rameshchandra Joshi
Vipulkumar Shankarbhai Pa-Tel
Brijeshkumar Patel
Pradeep Dinesh Shahi
Krunal Harishbhai Soni
Rajamannar Thennati
Muthukumaran Natarajan
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of ECSP20070185A publication Critical patent/ECSP20070185A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transmission And Conversion Of Sensor Element Output (AREA)

Abstract

La presente descripción se refiere a análogos novedosos del péptido similar al glucagón-1 (GLP-1) (7-37) que tienen una secuencia de aminoácidos con Leu o Ile en el C-terminal. Los nuevos análogos son potentes agonistas de GLP-1 con efecto adverso reducido y duración de la acción mejorada. La presente descripción se refiere además a derivados acilados de los nuevos análogos que tienen una potencia y duración de la acción mejoradas adicionalmente y son adecuados para la administración oral. Los análogos de la presente descripción pueden ser útiles en el tratamiento de la diabetes y la obesidad.
ECSENADI202070185A 2018-04-05 2020-11-05 Análogos novedosos de glp-1 ECSP20070185A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201821013109 2018-04-05
IN201821040468 2018-10-26
IN201821040474 2018-10-26

Publications (1)

Publication Number Publication Date
ECSP20070185A true ECSP20070185A (es) 2021-01-29

Family

ID=66589592

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202070185A ECSP20070185A (es) 2018-04-05 2020-11-05 Análogos novedosos de glp-1

Country Status (30)

Country Link
US (6) US11447535B2 (es)
EP (3) EP4364751A3 (es)
JP (2) JP7250814B2 (es)
KR (1) KR20200141469A (es)
CN (2) CN117964735A (es)
AU (2) AU2019247936C1 (es)
BR (1) BR112020020419A2 (es)
CA (1) CA3095988A1 (es)
CL (1) CL2020002574A1 (es)
CO (1) CO2020012425A2 (es)
DK (2) DK3774862T3 (es)
EC (1) ECSP20070185A (es)
ES (2) ES2980707T3 (es)
FI (1) FI4122954T3 (es)
HR (2) HRP20240749T1 (es)
HU (2) HUE067499T2 (es)
IL (1) IL277483A (es)
JO (1) JOP20200251A1 (es)
LT (2) LT4122954T (es)
MX (2) MX2020010505A (es)
PE (1) PE20211417A1 (es)
PH (1) PH12020551591A1 (es)
PL (2) PL4122954T3 (es)
PT (2) PT4122954T (es)
RS (2) RS63523B1 (es)
SG (1) SG11202009467YA (es)
SI (2) SI3774862T1 (es)
UA (1) UA128210C2 (es)
WO (1) WO2019193576A1 (es)
ZA (1) ZA202306729B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2980707T3 (es) * 2018-04-05 2024-10-02 Sun Pharmaceutical Ind Ltd Nuevos análogos de GLP-1
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
TW202216746A (zh) * 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型glp-1/gip雙重促效劑
US20240020543A1 (en) * 2020-10-17 2024-01-18 Sun Pharmaceutical Industries Limited Glp-1/gip dual agonists
CN114685646B (zh) * 2020-12-31 2023-04-07 厦门赛诺邦格生物科技股份有限公司 一种多肽侧链类似物的制备方法及其应用
IL304214B1 (en) 2021-01-20 2024-09-01 Viking Therapeutics Inc Preparations and methods for the treatment of metabolic and liver disorders
CN116514952B (zh) * 2022-10-13 2024-02-02 江苏师范大学 一类glp-1类似物及其应用
CN117756914B (zh) * 2023-12-15 2024-09-03 瀚晖制药有限公司 依柯胰岛素的制备方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
CN1271086C (zh) 1996-08-30 2006-08-23 诺沃挪第克公司 Glp-1衍生物
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
DE69942307D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
JP2002508162A (ja) 1998-02-27 2002-03-19 ノボ ノルディスク アクティーゼルスカブ N末端を短縮したglp−1誘導体
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するglp−1のglp−1誘導体及びエキセンジン
EP1060191B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Derivatives of glp-1 analogs
FR2777283B1 (fr) 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PT1137667E (pt) 1998-12-07 2005-02-28 Sod Conseils Rech Applic Analogos do glp-1
ES2321439T3 (es) 2000-06-16 2009-06-05 ELI LILLY & COMPANY Analogos del peptido-1 similar a glucagon.
ES2311560T3 (es) 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
MXPA04006679A (es) 2002-01-08 2004-11-10 Lilly Co Eli Analogos extendidos de peptido-1 de tipo glucagon.
KR20050049525A (ko) 2002-10-11 2005-05-25 가부시키가이샤산와카가쿠켄큐쇼 Glp-1 유도체 및 그의 경점막 흡수형 제제
EP1626981A4 (en) 2003-03-04 2006-11-22 Biorexis Pharmaceutical Corp PROTEINS PROTECTED AGAINST DIPEPTIDYLPEPTIDASE
ATE549028T1 (de) 2003-05-15 2012-03-15 Tufts College Stabile analoga von glp-1
BR122019021416A2 (es) 2003-09-19 2019-12-21
US7897566B2 (en) 2003-12-16 2011-03-01 Ipsen Pharma S.A.S. Analogues of GLP-1
JP2008515856A (ja) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性glp−1化合物
ES2484796T3 (es) 2005-03-18 2014-08-12 Novo Nordisk A/S Compuestos de GLP-1 extendidos
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
EP1883419A4 (en) 2005-05-06 2010-08-04 Bayer Pharmaceuticals Corp GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL USES
CN101262874A (zh) 2005-09-08 2008-09-10 塔夫茨大学信托人 稳定化的glp-1类似物
PL1767545T3 (pl) 2005-09-22 2010-04-30 Biocompatibles Uk Ltd Polipeptydy fuzyjne GLP-1 (glukagonopodobny peptyd-1) o zwiększonej odporności na peptydazy
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
EP2214691B1 (en) 2007-10-30 2015-09-30 Indiana University Research and Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
JP2013514322A (ja) 2009-12-16 2013-04-25 ノヴォ ノルディスク アー/エス 修飾されたn末端を有するglp−1受容体アゴニスト化合物
RU2531590C2 (ru) 2010-04-27 2014-10-20 Бета Фармасьютикалс,Ко,Лтд. Аналоги глюкагоноподобного пептида-1 и их применение
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
US9708383B2 (en) 2010-11-09 2017-07-18 Novo Nordisk A/S Double-acylated GLP-1 derivatives
AU2012241894B2 (en) 2011-04-12 2015-12-03 Novo Nordisk A/S Double-acylated GLP-1 derivatives
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
CN104039822A (zh) 2011-09-06 2014-09-10 诺沃—诺迪斯克有限公司 Glp-1衍生物
EP2578599A1 (en) 2011-10-07 2013-04-10 LanthioPep B.V. Cyclic analogs of GLP-1 and GLP-1 related peptides
JP6366575B2 (ja) 2012-05-08 2018-08-01 ノヴォ ノルディスク アー/エス 二重アシル化されたglp−1誘導体
JP6250034B2 (ja) 2012-05-08 2017-12-20 ノヴォ ノルディスク アー/エス 二重アシル化されたglp−1誘導体
CN104583234A (zh) 2012-06-14 2015-04-29 赛诺菲 毒蜥外泌肽-4肽类似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑
SG11201504215PA (en) 2012-12-21 2015-06-29 Sanofi Sa Functionalized exendin-4 derivatives
WO2014202727A1 (en) 2013-06-20 2014-12-24 Novo Nordisk A/S Glp-1 derivatives and uses thereof
US9738697B2 (en) 2013-06-23 2017-08-22 Wisconsin Alumni Research Foundation Alpha/beta-polypeptide analogs of glucagon-like peptide-1
EP3016975B1 (en) 2013-07-04 2019-01-16 Novo Nordisk A/S Derivatives of glp-1 like peptides, and uses thereof
CN105451776B (zh) 2013-08-15 2020-04-17 诺和诺德股份有限公司 Glp-1衍生物及其用途
AR098065A1 (es) * 2013-10-17 2016-04-27 Zealand Pharma As Análogos de glucagón acilados
BR112016013157A2 (pt) 2013-12-13 2017-09-26 Medimmune Ltd peptídeos resistentes à protease
WO2015086731A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
EP3226906B1 (en) 2014-11-27 2019-06-12 Novo Nordisk A/S Glp-1 derivatives and uses thereof
WO2016097108A1 (en) 2014-12-17 2016-06-23 Novo Nordisk A/S Glp-1 derivatives and uses thereof
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
US10111932B2 (en) 2015-08-26 2018-10-30 Syracuse University Coagonists of glucagon-like peptide 1 receptor and neuropeptide Y2 receptor
WO2017149070A1 (en) 2016-03-03 2017-09-08 Novo Nordisk A/S Glp-1 derivatives and uses thereof
BR112018072968A2 (pt) 2016-06-09 2019-02-19 Medimmune Limited peptídeos monolipidados resistentes às proteases
EP3534962B1 (en) 2016-11-07 2020-08-19 Novo Nordisk A/S Dchbs-active esters of peg compounds and their use
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類glp1/升糖素/gip受體促效劑之新化合物
WO2018178796A1 (en) * 2017-03-27 2018-10-04 Sun Pharmaceutical Industries Limited Method for making kex1 protease sensitive polypeptides using yeast strain
PL3704143T3 (pl) 2018-03-09 2024-04-15 Fresenius Kabi Ipsum S.R.L. Chemo-enzymatyczna synteza liraglutydu, semaglutydu i glp-1
ES2980707T3 (es) * 2018-04-05 2024-10-02 Sun Pharmaceutical Ind Ltd Nuevos análogos de GLP-1

Also Published As

Publication number Publication date
EP4122954B1 (en) 2024-04-03
DK4122954T3 (da) 2024-06-10
RS65639B1 (sr) 2024-07-31
LT3774862T (lt) 2022-09-12
SI3774862T1 (sl) 2022-10-28
US11485766B2 (en) 2022-11-01
US20200362007A1 (en) 2020-11-19
EP4364751A2 (en) 2024-05-08
HRP20240749T1 (hr) 2024-09-13
US20220402992A1 (en) 2022-12-22
PE20211417A1 (es) 2021-08-02
MX2024007688A (es) 2024-07-09
UA128210C2 (uk) 2024-05-08
BR112020020419A2 (pt) 2021-01-19
AU2023203430A1 (en) 2023-06-29
US20240199718A1 (en) 2024-06-20
HUE067499T2 (hu) 2024-10-28
FI4122954T3 (fi) 2024-06-18
SG11202009467YA (en) 2020-10-29
MX2020010505A (es) 2021-01-15
AU2019247936B2 (en) 2023-03-02
PL3774862T3 (pl) 2022-10-03
CO2020012425A2 (es) 2020-12-21
LT4122954T (lt) 2024-06-25
EP4122954A1 (en) 2023-01-25
PL4122954T3 (pl) 2024-08-12
CA3095988A1 (en) 2019-10-10
WO2019193576A1 (en) 2019-10-10
PT4122954T (pt) 2024-06-05
JP7250814B2 (ja) 2023-04-03
ES2925678T3 (es) 2022-10-19
PH12020551591A1 (en) 2021-08-16
SI4122954T1 (sl) 2024-07-31
JOP20200251A1 (ar) 2020-10-04
PT3774862T (pt) 2022-09-05
DK3774862T3 (da) 2022-09-05
IL277483A (en) 2020-11-30
CN112236444A (zh) 2021-01-15
CN117964735A (zh) 2024-05-03
CL2020002574A1 (es) 2021-06-04
US11873328B2 (en) 2024-01-16
US20210206823A1 (en) 2021-07-08
US11866477B2 (en) 2024-01-09
US20190309040A1 (en) 2019-10-10
JP2021520346A (ja) 2021-08-19
EP3774862A1 (en) 2021-02-17
HRP20221054T1 (hr) 2022-11-11
ES2980707T3 (es) 2024-10-02
US11242373B2 (en) 2022-02-08
ZA202306729B (en) 2024-03-27
AU2019247936C1 (en) 2023-06-15
US11447535B2 (en) 2022-09-20
EP3774862B1 (en) 2022-06-08
US20220402991A1 (en) 2022-12-22
HUE060135T2 (hu) 2023-02-28
JP2023078367A (ja) 2023-06-06
RS63523B1 (sr) 2022-09-30
KR20200141469A (ko) 2020-12-18
EP4364751A3 (en) 2024-06-26
AU2019247936A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
ECSP20070185A (es) Análogos novedosos de glp-1
PE20170954A1 (es) Compuestos co-agonistas de gip y glp-1
AR067555A1 (es) Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal
CL2021000158A1 (es) Compuestos coagonistas de gip/glp1
PE20220590A1 (es) Agonistas del receptor del peptido-1 similar al glucagon
CO6280539A2 (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabolicos y obesidad
CO2021012380A2 (es) Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa humana ph20 y un medicamento
CO2019005924A2 (es) Agonistas duales acilados de glp-1/glp-2
PE20180158A1 (es) Coagonistas de los receptores de glucagon y de glp-1
AR099975A1 (es) Derivados de exendina-4 como agonistas peptídicos duales del receptor de glp-1 / glucagón
PE20191143A1 (es) Nuevos compuestos como agonistas peptidicos trigonales de los receptores de glp1/glucagon/gip
RU2011129784A (ru) Основанные на амидах пролекарства пептидов глюкагонового надсемейства
PE20151770A1 (es) Compuesto peptidico
AR094181A1 (es) Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon
PE20170087A1 (es) Composicion para tratar la diabetes mellitus, que comprende insulina y un agonista doble de glp-1/glucagon
PE20100255A1 (es) Co-agonistas del receptor de glucagon/glp-1
PE20200606A1 (es) Composiciones solidas para administracion oral
AR069136A1 (es) Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1 (peptido somilar al glucagon tipo 1) y usos de los mismos
BR112022023834A2 (pt) Composto duplo-agonista para os receptores de glp-1 e gip e aplicação do mesmo
PE20171380A1 (es) Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada
GT201700224A (es) Proteína de unión a rgma y su uso
PE20221518A1 (es) Analogos de incretina y sus usos
CL2020002718A1 (es) Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos.
AR128464A1 (es) Péptidos agonistas duales glp-1 y glucagón con estabilidad biológica mejorada
EA202092017A1 (ru) Новые аналоги glp-1